Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio
Ventyx Biosciences Announces $100 Million Private Placement of Common Stock
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024
Ventyx Biosciences earnings beat by $0.08
Ventyx to host virtual investor event on March 11th to provide clinical updates on our NLRP3 portfolio and from the open-label extension of the VTX002 Phase 2 trial in ulcerative colitis Cash, cash...
Results of the Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis to be highlighted in oral presentation on February 22nd SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ventyx...
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (Ventyx), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a...
SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (Ventyx), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a...
Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference